By VETTAPHARMA reporter: The U.S. Food and Drug Administration (FDA) announced it intends to take decisive action against non-FDA-approved GLP-1 drugs, particularly compounded versions being marketed as alternatives to authorized prescription therapies. The announcement was issued in an official press release by Martin A. Makary, M.D., M.P.H., Commissioner of Food and Drugs.
According to the FDA statement, the agency is focused on restricting active pharmaceutical ingredients (APIs) used in non-FDA-approved compounded GLP-1 drugs. These products have been marketed by some companies — including telehealth firms and compounding pharmacies — as similar alternatives to therapies that are formally evaluated for safety and effectiveness. The FDA cannot verify the quality, safety, or efficacy of these unapproved compounded versions.
The GLP-1 class of medications — which includes treatments widely prescribed for diabetes and chronic weight management — has surged in demand in recent years, contributing to the proliferation of compounded alternatives that have not undergone FDA review. In announcing its intent to enforce against these products, the FDA reaffirmed its commitment to safeguarding public health.
In its press announcement, the agency emphasized that advertising and promotional materials for compounded products must not mislead the public by claiming equivalence with FDA-approved drugs or suggesting they contain the “same active ingredient” or produce similar clinical results. Companies that fail to address violations may face legal actions — including seizures and injunctions — without further notice, the statement said.
The regulatory action specifically mentions Hims & Hers as one of the entities engaged in mass-marketing compounded GLP-1 drugs that are not approved by the FDA. According to the agency, firms involved in the manufacture, distribution, or marketing of such products should expect increasing enforcement, and failure to address violations could result in legal action, including possible seizures or injunctions without further notice.
In addition, the FDA noted that it is taking steps to combat misleading direct-to-consumer marketing and advertising related to these unapproved products, building on warning letters issued in the fall of 2025.
The agency did not provide a precise number of companies immediately affected but made clear that its compliance and enforcement tools will be employed broadly where appropriate.
The FDA’s actions reflect heightened regulatory scrutiny of compounded GLP-1 drugs, which some health advocates and regulators have raised concerns about due to unverified manufacturing quality and unknown safety profiles.
Disclaimer: The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
